JP2020533953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533953A5 JP2020533953A5 JP2020501133A JP2020501133A JP2020533953A5 JP 2020533953 A5 JP2020533953 A5 JP 2020533953A5 JP 2020501133 A JP2020501133 A JP 2020501133A JP 2020501133 A JP2020501133 A JP 2020501133A JP 2020533953 A5 JP2020533953 A5 JP 2020533953A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- monoclonal antibody
- nucleic acid
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 67
- 108091007433 antigens Proteins 0.000 claims description 67
- 102000036639 antigens Human genes 0.000 claims description 67
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- 150000007523 nucleic acids Chemical group 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 22
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 210000004408 hybridoma Anatomy 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 229940027941 immunoglobulin g Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 229940113720 aminosalicylate Drugs 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 101150066838 12 gene Proteins 0.000 description 1
- 101150078635 18 gene Proteins 0.000 description 1
- 101150109698 A2 gene Proteins 0.000 description 1
- 101150051089 A3 gene Proteins 0.000 description 1
- 101150040566 B3 gene Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532809P | 2017-07-14 | 2017-07-14 | |
| US62/532,809 | 2017-07-14 | ||
| PCT/US2018/042052 WO2019014572A1 (en) | 2017-07-14 | 2018-07-13 | ANTIBODIES DIRECTED AGAINST MADCAM |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533953A JP2020533953A (ja) | 2020-11-26 |
| JP2020533953A5 true JP2020533953A5 (enExample) | 2021-02-25 |
| JP7160491B2 JP7160491B2 (ja) | 2022-10-25 |
Family
ID=63209653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501133A Active JP7160491B2 (ja) | 2017-07-14 | 2018-07-13 | ＭＡｄＣＡＭに対する抗体 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20190169291A1 (enExample) |
| EP (1) | EP3652211A1 (enExample) |
| JP (1) | JP7160491B2 (enExample) |
| KR (1) | KR102787394B1 (enExample) |
| CN (2) | CN118406148A (enExample) |
| AR (1) | AR112336A1 (enExample) |
| AU (1) | AU2018300189B2 (enExample) |
| BR (1) | BR112020000698A2 (enExample) |
| CA (1) | CA3069914A1 (enExample) |
| CL (1) | CL2020000102A1 (enExample) |
| CO (1) | CO2020000352A2 (enExample) |
| CR (1) | CR20200076A (enExample) |
| CU (1) | CU20200002A7 (enExample) |
| DO (1) | DOP2020000005A (enExample) |
| EA (1) | EA202090286A1 (enExample) |
| EC (1) | ECSP20011317A (enExample) |
| IL (1) | IL272015A (enExample) |
| MA (1) | MA48241A1 (enExample) |
| MX (1) | MX2023014363A (enExample) |
| NI (1) | NI202000004A (enExample) |
| PE (1) | PE20200616A1 (enExample) |
| PH (1) | PH12020500100A1 (enExample) |
| SG (1) | SG11202000298VA (enExample) |
| TW (1) | TW201920266A (enExample) |
| WO (1) | WO2019014572A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP2025538586A (ja) | 2022-11-22 | 2025-11-28 | 武田薬品工業株式会社 | 非アルコール性脂肪性肝炎の治療のためのＭＡｄＣＡＭ－１抗体の投薬レジメン |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US20040010810A1 (en) | 1990-01-12 | 2004-01-15 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| WO1993016043A1 (en) | 1992-02-18 | 1993-08-19 | Otsuka Kagaku Kabushiki Kaisha | β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| AU5675794A (en) | 1992-12-15 | 1994-07-04 | Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
| AU693436B2 (en) | 1993-03-09 | 1998-07-02 | Genzyme Corporation | Isolation of components of interest from milk |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5698679A (en) | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| ATE366809T1 (de) | 1995-02-10 | 2007-08-15 | Millennium Pharm Inc | Addressine der schleimhaut und der blutgefässe und ihre verwendung |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| AU705616B2 (en) | 1995-04-21 | 1999-05-27 | Cell Genesys, Inc. | Generation of large genomic DNA deletions |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0773288A3 (en) | 1995-08-29 | 1997-07-09 | Kirin Brewery | Chimera animal and its method of manufacture |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| KR20010034554A (ko) | 1998-03-03 | 2001-04-25 | 레이몬드, 엠. 위티 | 치료제로서의 ｃｄ147 결합 분자 |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US7090845B2 (en) | 1998-05-13 | 2006-08-15 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
| JP4817494B2 (ja) | 1998-05-13 | 2011-11-16 | ジェネンテック， インコーポレイテッド | 肝疾患の診断及び治療 |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| JP2003533968A (ja) | 1999-09-03 | 2003-11-18 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 免疫グロブリンスーパーファミリーポリヌクレオチド、ポリペプチド、および抗体 |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| JP2003089656A (ja) | 2001-09-19 | 2003-03-28 | Nippon Kayaku Co Ltd | 移植による免疫反応抑制剤 |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| KR20040105740A (ko) | 2002-02-25 | 2004-12-16 | 엘란 파마슈티칼스, 인크. | 염증 치료제의 투여 방법 |
| US20070202097A1 (en) | 2003-03-10 | 2007-08-30 | Krissansen Geoffrey W | Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| DOP2005000002A (es) * | 2004-01-09 | 2005-08-15 | Pfizer | "anticuerpos contra madcam" |
| WO2005076843A2 (en) | 2004-02-06 | 2005-08-25 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating tumors and metastatic disease |
| EP1865986B1 (en) * | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| CN101325968B (zh) * | 2005-03-08 | 2014-04-23 | 辉瑞产品公司 | 抗ctla-4抗体组合物 |
| US20100119517A1 (en) | 2005-07-08 | 2010-05-13 | Pfizer Inc | Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue |
| PE20070374A1 (es) | 2005-07-08 | 2007-05-12 | Pfizer Ltd | ANTICUERPOS ANTI-MAdCAM |
| EP1904100A1 (en) | 2005-07-11 | 2008-04-02 | Pfizer Limited | New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
| WO2007007160A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
| WO2007007152A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
| WO2007007151A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
| WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
| US8081772B2 (en) | 2008-11-20 | 2011-12-20 | Gentex Corporation | Vehicular microphone assembly using fractional power phase normalization |
| JP6615745B2 (ja) | 2013-03-27 | 2019-12-04 | ジェネンテック， インコーポレイテッド | ベータ７インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用 |
| CA2916283C (en) | 2015-01-09 | 2024-07-02 | Pfizer Inc. | MADCAM ANTAGONIST DOSING REGIMEN |
-
2018
- 2018-07-13 KR KR1020207004168A patent/KR102787394B1/ko active Active
- 2018-07-13 AR ARP180101961 patent/AR112336A1/es unknown
- 2018-07-13 PE PE2020000060A patent/PE20200616A1/es unknown
- 2018-07-13 WO PCT/US2018/042052 patent/WO2019014572A1/en not_active Ceased
- 2018-07-13 TW TW107124340A patent/TW201920266A/zh unknown
- 2018-07-13 CA CA3069914A patent/CA3069914A1/en active Pending
- 2018-07-13 MA MA48241A patent/MA48241A1/fr unknown
- 2018-07-13 CR CR20200076A patent/CR20200076A/es unknown
- 2018-07-13 SG SG11202000298VA patent/SG11202000298VA/en unknown
- 2018-07-13 EA EA202090286A patent/EA202090286A1/ru unknown
- 2018-07-13 AU AU2018300189A patent/AU2018300189B2/en active Active
- 2018-07-13 BR BR112020000698-0A patent/BR112020000698A2/pt not_active IP Right Cessation
- 2018-07-13 CN CN202410182126.9A patent/CN118406148A/zh active Pending
- 2018-07-13 EP EP18755583.4A patent/EP3652211A1/en active Pending
- 2018-07-13 JP JP2020501133A patent/JP7160491B2/ja active Active
- 2018-07-13 CN CN201880056875.XA patent/CN111032694B/zh active Active
- 2018-07-13 US US16/035,178 patent/US20190169291A1/en not_active Abandoned
- 2018-07-13 CU CU2020000002A patent/CU20200002A7/es unknown
-
2020
- 2020-01-09 DO DO2020000005A patent/DOP2020000005A/es unknown
- 2020-01-13 CL CL2020000102A patent/CL2020000102A1/es unknown
- 2020-01-13 IL IL272015A patent/IL272015A/en unknown
- 2020-01-13 NI NI202000004A patent/NI202000004A/es unknown
- 2020-01-14 CO CONC2020/0000352A patent/CO2020000352A2/es unknown
- 2020-01-14 MX MX2023014363A patent/MX2023014363A/es unknown
- 2020-01-14 PH PH12020500100A patent/PH12020500100A1/en unknown
- 2020-02-13 EC ECSENADI202011317A patent/ECSP20011317A/es unknown
-
2021
- 2021-06-04 US US17/338,991 patent/US11802156B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240368263A1 (en) | Optimized anti-tl1a antibodies | |
| CN109843927B (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| US20200255516A1 (en) | Tigit antibody, antigen-binding fragment thereof, and medical use thereof | |
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2019527553A5 (enExample) | ||
| CN116239698A (zh) | 双功能融合蛋白及其医药用途 | |
| JP2009005695A5 (enExample) | ||
| JP2022509156A (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2020535799A5 (enExample) | ||
| JP2022518588A (ja) | 抗ｐｄ－１抗体、その抗原結合フラグメントおよびそれらの医薬用途 | |
| WO2022105914A1 (zh) | Cd70抗体及其应用 | |
| CN114667296B (zh) | 一种双特异性抗体及其用途 | |
| JP2020534012A5 (enExample) | ||
| CN115109156A (zh) | 一种靶向bcma的纳米抗体及其应用 | |
| KR20210016056A (ko) | 항-bcma 항체 및 그 용도 | |
| CN113227148A (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| CN111763258B (zh) | 抗ox40抗体及其用途 | |
| US20230357391A1 (en) | Cd47 binding agents and uses thereof | |
| WO2024187743A1 (zh) | 抗cd27单克隆抗体及其应用 | |
| TW202413405A (zh) | 抗體、其抗原結合片段及其藥物用途 | |
| WO2016061632A1 (en) | Fn14-binding proteins and uses thereof | |
| HK40070151B (en) | Bispecific antibody and use thereof |